In the landscape of modern drug discovery, a quiet revolution is unfolding within the archives of pathology laboratories. For decades, the process of histological analysis was linear and terminal: a pathologist would examine a glass slide, dictate a report, and file the specimen away in a cabinet, often never to be touched again. Today, however, that one-way street has become a circular engine of discovery.
Driven by the forced digitization necessitated by the COVID-19 pandemic and empowered by the maturation of artificial intelligence (AI), digital pathology is evolving from a mere remote-work tool into a powerful analytical platform. By "mining" existing tissue samples and historical study data, researchers are uncovering molecular insights that were previously inaccessible, effectively reducing the need for future animal testing and ushering in a new era of preclinical efficiency.
The Shift: From Glass Slides to Digital Data
Traditionally, the pathology endpoint was defined exclusively by the human expert’s written report. Today, that endpoint is a rich digital file—a collection of pixels containing vast, untapped biological information.
Dr. Aleksandra Zuraw, a veterinary pathologist at Charles River Laboratories, notes that this transition represents a fundamental change in how science treats its own history. "Before, the pathology endpoint was just a report," Dr. Zuraw explains. "Now you have the digitized slide, which is pixels." These pixels can be interrogated by machine learning models to identify patterns linked to molecular changes, allowing a single slide to serve as a data repository for questions that were never conceived at the time the slide was first created.
Chronology of a Regulatory Shift
The move toward reducing animal reliance has been accelerated by both technological capability and shifting legal frameworks.
- 2020–2022 (The Pandemic Catalyst): The global crisis forced pathologists to adopt digital workflows to maintain operations, proving the viability of high-resolution digital slide review. Simultaneously, the FDA Modernization Act 2.0 (2022) signaled a pivotal shift in US regulatory policy, legally allowing non-animal methods to support human trial applications.
- April 2024: Charles River Laboratories launched its "Alternative Methods Advancement Project," a strategic commitment to integrate these new approach methodologies (NAMs) into standard practice.
- April 2025: The FDA released its long-awaited roadmap for reducing animal testing in preclinical safety studies. This roadmap prioritized a phased transition, starting with monoclonal antibodies and expanding toward chemical entities.
- September 2026: Further regulatory updates from the FDA cemented the agency’s goal: to transform animal studies from the "default" requirement into the exception, making NAMs the primary path for drug safety assessment within three to five years.
Supporting Data: Virtual Controls and Archived Tissue
The most immediate impact of this transformation is found in the optimization of existing animal studies. Currently, a standard toxicology trial requires "concurrent control groups"—animals that undergo the exact same conditions as the test subjects but receive no drug. Because control groups make up a significant portion of every study, they represent a massive, necessary use of animal lives.
The Power of Virtual Controls
Charles River is currently building the infrastructure for "virtual control groups." By leveraging vast databases of historical study data, researchers can create high-fidelity baselines that replace the need for concurrent control animals. As Dr. Zuraw points out, this is a matter of "simple arithmetic." By matching historical data to new study conditions, the total number of animals required to achieve statistical significance drops precipitously.
Unlocking the FFPE Archive
For decades, laboratories have stored thousands of formalin-fixed, paraffin-embedded (FFPE) tissue blocks. These blocks are time capsules of biological response. While fresh-frozen tissue is ideal for molecular studies, it requires pre-planning. When an unforeseen question arises after a study is completed, researchers historically had no choice but to start a new experiment.
New protocols, supported by 2025 OECD guidance on omics analysis, provide a roadmap for extracting meaningful gene expression and protein data from these archival FFPE blocks. By applying advanced molecular assays to these samples, researchers can gain the insights they need without sacrificing additional animals. As Zuraw notes, "You don’t lose the context of the study. You can extract more from the same animals, from the same blocks, without running a new experiment."
Official Perspectives and Industry Standards
The scientific community is increasingly viewing these methods not as experimental "add-ons," but as the future of the industry. The integration of digital pathology into clinical and preclinical workflows has sparked a "snowball effect" in data accessibility.
Dr. Syed T. Hoda, director of digital pathology at NYU, has been at the forefront of this, spearheading initiatives to transition massive departments to full digital sign-out. This is a prerequisite for the broader adoption of AI-driven pathology; if the data is not digitized, it cannot be processed by the advanced algorithms now capable of performing "virtual staining."
Virtual staining, a cutting-edge technique that allows software to generate the appearance of a stain on an unstained tissue section, is perhaps the most visible indicator of this progress. While most current methods still require a glass slide to be scanned, the industry is rapidly moving toward protocols that skip the glass and the staining process entirely, moving directly to digital image generation.
The Implications: A "Snowball Effect" for Animal Welfare
The transition toward digital-first pathology carries profound implications for the ethics and speed of drug discovery.
1. Ethical Stewardship
The FDA’s push toward making animal studies the exception rather than the norm is the strongest driver of this change. By mining old tissue and utilizing virtual controls, the scientific community is fulfilling its ethical mandate to refine, reduce, and replace animal use (the "3Rs").
2. Scientific Precision
Digital pathology is not merely a tool for efficiency; it is a tool for accuracy. Molecular prediction from H&E-stained slides allows researchers to see nuances in tissue architecture that the human eye might overlook. As these methods are validated, they will provide a level of sensitivity in toxicology that was previously unattainable, leading to safer drugs reaching the market faster.
3. The Need for Precedent
The primary challenge remains the culture of innovation. As Dr. Zuraw emphasizes, the industry needs "early adopters" to generate the evidence required by regulators. "You still need enough early adopters to generate precedent," she states. "Those early adopters will embrace the guidance, figure it out and troubleshoot, and then others can build on their work without reinventing the wheel."
Conclusion
The transformation of the pathology laboratory from a warehouse of glass to a hub of digital data is one of the most significant shifts in 21st-century medicine. By recognizing that historical data—once considered "used"—is actually a goldmine of untapped biological intelligence, the scientific community is creating a self-sustaining cycle of innovation.
As digital pathology continues to evolve, the reliance on animal models will naturally recede, replaced by the sophisticated, data-driven insights of an industry that has finally learned to look backward to move forward. The goal is no longer just to complete a study; it is to extract the maximum amount of truth from every experiment, ensuring that every animal utilized contributes to a deeper understanding of human health.
About the Author
